# Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

> **NCT04886531** · PHASE2 · RECRUITING · sponsor: **Ruth O'Regan** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- ER Positive Breast Cancer
- PR-Positive Breast Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Letrozole (L) or Anastrozole (A)
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04886531
- **Lead sponsor:** Ruth O'Regan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2026-06-22
- **Final completion:** 2027-07-21
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886531, "Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04886531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*